Protagenic Therapeutics, Inc.\new financial data

Symbol
PTIX, PTIXW on Nasdaq
Location
149 Fifth Avenue, Suite 500, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Atrinsic, Inc. (to 6/20/2016), NEW MOTION, INC. (to 6/30/2009), MPLC, Inc. (to 4/2/2007), MILLBROOK PRESS INC (to 5/23/2005)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 439 % -37%
Debt-to-equity 28.4 % +56.4%
Return On Assets -186 % -315%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.47M shares +3.15%
Common Stock, Shares, Outstanding 4.47M shares +3.15%
Entity Public Float 8.79M USD -29.7%
Common Stock, Value, Issued 447 USD +3%
Weighted Average Number of Shares Outstanding, Basic 4.44M shares +2.59%
Weighted Average Number of Shares Outstanding, Diluted 4.44M shares +2.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 4.96M USD +179%
General and Administrative Expense 1.24M USD -18.4%
Operating Income (Loss) -6.05M USD -74.7%
Nonoperating Income (Expense) -354K USD -4261%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.4M USD -85.4%
Net Income (Loss) Attributable to Parent -6.4M USD -85.4%
Earnings Per Share, Basic -1.45 USD/shares -81.3%
Earnings Per Share, Diluted -1.45 USD/shares -28.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current 1.59M USD -78.8%
Assets, Current 1.37M USD -80.2%
Property, Plant and Equipment, Net 98.2K USD +6056%
Assets 1.47M USD -78.8%
Liabilities, Current 675K USD -55.2%
Liabilities 675K USD -55.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -130K USD +77.8%
Retained Earnings (Accumulated Deficit) -34.1M USD -23.1%
Stockholders' Equity Attributable to Parent 793K USD -85.4%
Liabilities and Equity 1.47M USD -78.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.66M USD -346%
Net Cash Provided by (Used in) Investing Activities 1.2M USD +308%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.47M shares +3.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -456K USD -495%
Deferred Tax Assets, Valuation Allowance 7.07M USD +27.2%
Deferred Tax Assets, Gross 7.07M USD +27.2%
Depreciation 12.6K USD +13714%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.95M USD -65.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 35M USD +3.93%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 108K USD -21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%